Urologic oncology Journal

Overview
Identity
View All

publication venue for

Adapting patient priorities care for older adults with non-muscle-invasive bladder cancer: A qualitative inquiry.. 44:-. 2026
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort study.. 43:695.e21-695.e29. 2025
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.. 43:639-653. 2025
Prehabilitation: Cognitive considerations. 2025
What motivates bladder cancer patients to be active? A qualitative study assessing attitudes towards physical activity and digital health technologies.. 43:522.e1-522.e8. 2025
Associations of a claims-based frailty index with perioperative outcomes and survival among older adults undergoing radical cystectomy for bladder cancer.. 43:521.e9-521.e17. 2025
Prospective evaluation of comprehensive geriatric assessments in multidisciplinary bladder cancer care and implications for personalized vulnerability phenotyping.. 43:468.e7-468.e18. 2025
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.. 43:286-296. 2025
Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials.. 42:223-228. 2024
Interruptions in bladder cancer care during the COVID-19 public health emergency.. 42:116.e17-116.e21. 2023
Engaging disparities in prostate cancer: Piloting an interactive, virtual workshop to educate providers on shared decision-making for underserved populations.. 41:430.e1-430.e7. 2023
A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy.. 41:51.e25-51.e31. 2022
Prognostic Value of Sarcopenia and Albumin in the Surgical Management of Localized Renal Cell Carcinoma.. 41:50.e19-50.e26. 2022
Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events.. 40:456.e19-456.e30. 2022
Gene network profiling in muscle-invasive bladder cancer: A systematic review and meta-analysis.. 40:197.e11-197.e23. 2022
Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic.. 41:65-68. 2021
A 25-year perspective on advances in the study of the epidemiology, disparities, and outcomes of urologic cancers.. 39:595-601. 2021
Research highlights of the 2020 society of urologic oncology young urologic oncologists' program.. 39:452-454. 2021
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy.. 39:496.e1-496.e8. 2021
Prostate cancer presentation, treatment selection, and outcomes among men with HIV/AIDS: A clinical stage, race, and age-matched contemporary analysis.. 39:73.e19-73.e25. 2020
Introduction: Personalizing risk stratification in bladder cancer: Moving away from "the eyeball test" and embracing objective quantification of risk.. 38:695-697. 2020
Assessments of frailty in bladder cancer.. 38:698-705. 2020
Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults.. 38:737.e17-737.e23. 2020
Risk stratification metrics for bladder cancer: Comprehensive Geriatric Assessments.. 38:725-733. 2020
External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system.. 38:39.e21-39.e27. 2019
Patterns of stereotactic body radiation therapy: The influence of lung cancer treatment on prostate cancer treatment.. 38:37.e21-37.e27. 2019
Urologic oncology workforce diversity: A first step in reducing cancer disparities.. 40:120-125. 2019
Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists.. 36:501.e15-501.e21. 2018
Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial.. 36:340.e1-340.e6. 2018
Determinants of the overuse of imaging in low-risk prostate cancer: A systematic review.. 35:647-658. 2017
Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort.. 35:662.e17-662.e21. 2017
National treatment trends among older patients with T1-localized renal cell carcinoma.. 35:113.e15-113.e21. 2016
Predictors of prostate cancer screening using Andersen's Behavioral Model of Health Services Use.. 34:529.e9-529.e14. 2016
Unmet informational and supportive care needs of patients following cystectomy for bladder cancer based on age, sex, and treatment choices.. 34:531.e7-531.e14. 2016
Oncologic surveillance in bladder cancer following radical cystectomy: A systematic review and meta-analysis.. 34:236.e13-21. 2016
Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach.. 33:339.e1-8. 2015
The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy.. 33:388.e11-8. 2015
The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma.. 33:67.e15-23. 2014
The future of quality in urologic oncology: evaluating the horizon of surgical standards.. 32:735-40. 2014
Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression.. 23:261-7. 2005